佐剂
免疫系统
CD8型
人口
干扰素
免疫学
生物
接种疫苗
疫苗佐剂
细胞免疫
免疫
信号转导
T细胞
化学
细胞生物学
医学
环境卫生
作者
Xiaofan Ding,Mengxue Sun,Fusheng Guo,Xinmin Qian,Haoyu Yuan,Wenjiao Lou,Qixuan Wang,Xiaoguang Lei,Wenwen Zeng
标识
DOI:10.1002/advs.202310108
摘要
Abstract New adjuvants that trigger cellular immune responses are urgently needed for the effective development of cancer and virus vaccines. Motivated by recent discoveries that show activation of type I interferon (IFN‐I) signaling boosts T cell immunity, this study proposes that targeting this pathway can be a strategic approach to identify novel vaccine adjuvants. Consequently, a comprehensive chemical screening of 6,800 small molecules is performed, which results in the discovery of the natural compound picrasidine S (PS) as an IFN‐I inducer. Further analysis reveals that PS acts as a powerful adjuvant, significantly enhancing both humoral and cellular immune responses. At the molecular level, PS initiates the activation of the cGAS‐IFN‐I pathway, leading to an enhanced T cell response. PS vaccination notably increases the population of CD8+ central memory (T CM )‐like cells and boosts the CD8+ T cell‐mediated anti‐tumor immune response. Thus, this study identifies PS as a promising candidate for developing vaccine adjuvants in cancer prevention.
科研通智能强力驱动
Strongly Powered by AbleSci AI